Published in Oncotarget on March 22, 2016
Prognostic value of decreased GRK6 expression in lung adenocarcinoma. J Cancer Res Clin Oncol (2016) 0.78
Activin A Stimulates Migration of the Fallopian Tube Epithelium, an Origin of High-Grade Serous Ovarian Cancer, through Non-Canonical Signaling. Cancer Lett (2017) 0.75
Prognostic significance of TCF21 mRNA expression in patients with lung adenocarcinoma. Sci Rep (2017) 0.75
TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol (2007) 6.34
Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol (2011) 4.72
Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci U S A (1998) 1.86
Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res (2008) 1.82
Activation of signalling by the activin receptor complex. Mol Cell Biol (1996) 1.79
Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood) (2002) 1.67
Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. J Clin Oncol (2015) 1.65
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res (2003) 1.58
Role of activin-A in cigarette smoke-induced inflammation and COPD. Eur Respir J (2013) 1.52
Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies. Eur J Clin Invest (2012) 1.45
Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev (2006) 1.30
Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics (2009) 1.19
Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res (2003) 1.19
Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer (2004) 1.16
Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PLoS One (2013) 1.15
Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol (2005) 1.08
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res (2008) 1.08
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis (2006) 1.06
Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol (1986) 1.03
Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res (2007) 1.02
Serum and tissue expression of activin a in postmenopausal women with breast cancer. J Clin Endocrinol Metab (2002) 1.02
Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta (2014) 1.01
Follistatin binds to both activin and inhibin through the common subunit. Endocrinology (1991) 1.01
Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer (2013) 1.00
Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia (2009) 1.00
Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol (2006) 0.98
Activin a causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. Ann Surg Oncol (2007) 0.97
Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol (2011) 0.97
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res (2007) 0.96
The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax (2012) 0.94
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer (2015) 0.94
High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer (2013) 0.93
New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol (2011) 0.92
Identification and characterization of follistatin as a novel angiogenin-binding protein. FEBS Lett (2007) 0.91
Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Med Oncol (2014) 0.90
Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition. Oncogene (2004) 0.89
Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res (2001) 0.89
INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma. J Thorac Oncol (2009) 0.88
Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis (2010) 0.87
Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study. Cardiovasc Diabetol (2013) 0.87
Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomark (2010) 0.86
Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab (1998) 0.85
Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. Diabetes Metab Res Rev (2013) 0.83
Tumour necrosis factor-α stimulates human neutrophils to release preformed activin A. Immunol Cell Biol (2011) 0.83
Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer. Cancer Epidemiol Biomarkers Prev (2015) 0.83
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer (2012) 0.82
Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. Lung Cancer (2007) 0.82
The Haptoglobin β chain as a supportive biomarker for human lung cancers. Mol Biosyst (2011) 0.82
Activin A immunoexpression as predictor of occult lymph node metastasis and overall survival in oral tongue squamous cell carcinoma. Head Neck (2014) 0.81
Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. Br J Cancer (2015) 0.80
Expression of Cripto-1 gene protein and Activin-A in human lung adenocarcinoma tissue. Pak J Pharm Sci (2015) 0.78
Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation. Oncol Lett (2015) 0.77
Low miR-143/miR-145 Cluster Levels Induce Activin A Overexpression in Oral Squamous Cell Carcinomas, Which Contributes to Poor Prognosis. PLoS One (2015) 0.77
Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma. Oncotarget (2015) 0.77
Gene-expression Profiling in Non-small Cell Lung Cancer with Invasion of Mediastinal Lymph Nodes for Prognosis Evaluation. Cancer Genomics Proteomics (2015) 0.77
Activin A is anti-lymphangiogenic in a melanoma mouse model. J Invest Dermatol (2014) 0.77
Follistatin is a novel biomarker for lung adenocarcinoma in humans. PLoS One (2014) 0.76
Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival? Cancer Res Treat (2015) 0.76
Lung cancer in never smokers. Future Oncol (2011) 0.88
Light-assisted small-molecule screening against protein kinases. Nat Chem Biol (2015) 0.79
Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur J Cancer (2016) 0.75